Sprint Interval Training on the Endurance, Strength and Velocity Capacities of Healthy Sedentary Subjects (BénéfiSIT)

July 18, 2023 updated by: Centre Hospitalier Universitaire de Saint Etienne

Sprint Interval Training (SIT) on the Endurance, Strength and Velocity Capacities of Healthy Sedentary Subjects

The present study aims to analyse first, the acute effects generated by a single bout of Sprint Interval Training (SIT) and, secondly, the effects of a long-term intervention on sedentary participants.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The main goal is to determine the optimal dose of high-intensity exercise that enhances the best physiological adaptations.

The cumulative effects of SIT, will be assessed by a series of measures placed throughout the time-course (before, after the 1st , the 2nd and the 3rd block of SIT). Those measures consist of physiological measurements (VO2max), neuromuscular capacities (force-velocity profile) the autonomic nervous system responses (heart rate variability) and blood markers (lactate, Creatine phosphoKinase (CK), cytokinases, µRNA). Acute effects will be measured in the familiarisation sessions (after short (8 sprints) and long (14 sprints) sets) by performing a battery of neuromuscular, perceptual, and autonomic nervous system tests before and after the single session of SIT.

Study Type

Interventional

Enrollment (Actual)

23

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Saint-Étienne, France, 42055
        • CHU de Saint-Etienne

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • untrained healthy (less than 2 hours of sport per week)
  • free from muscular, bone or joint injuries
  • free from neurologic disease

Exclusion Criteria:

  • taking neuroactive substances that can alter corticospinal excitability
  • Heart or respiratory failure.
  • Subjects who have taken corticosteroids within 3 months (inhalation, infiltration or history of corticosteroid therapy).
  • Pregnant woman
  • Subject under guardianship

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Sedentary participants

Series of measures placed throughout the time-course (before, after the 1st , the 2nd and the 3rd block of SIT).

These measurements consist of physiological measurements (VO2max), neuromuscular capacities (force-speed profile), autonomic nervous system responses (heart rate variability) and blood markers (lactate, CK, cytokinases, µRNA).
Other: Sprint Interval Training

The Sprint Interval Training (SIT) training consists of 3 successive blocks of 5 training sessions each. The sessions are 24 to 48 hours apart.

. One block lasts two weeks. After the end of one block, the following block begins the day after.

The Sprint Interval Training lasts 6 weeks.

Each session consists of a series of sprints, the number of which varies from 8 to 14. Thus a session will last from 30 to 45 min approximately

So, the time frame of this study is Baseline, Block 1, Block 2 and Block 3 (Not in day or week or month)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
oxygen uptake (VO2max) - ml/min/kg
Time Frame: At the end of the 1st, 2nd and 3rd block : Each block = 2 weeks; each block is 1 day apart

consumption oxygen uptake (VO2max) measured on a cycle ergometer

The main objective is to determine at which time frame of sprint interval training blocks, the endurance performance (VO2max) is best.
At the end of the 1st, 2nd and 3rd block : Each block = 2 weeks; each block is 1 day apart

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Maximum power (W)
Time Frame: At the end of the 1st, 2nd and 3rd block : Each block = 2 weeks; each block is 1 day apart
It is measured thanks to the force-speed profile using two sprints of 7s with braking forces of 0 , 4 and 0.7 N.kg-1 respectively.
At the end of the 1st, 2nd and 3rd block : Each block = 2 weeks; each block is 1 day apart
Maximum theoretical force (N.m)
Time Frame: At the end of the 1st, 2nd and 3rd block : Each block = 2 weeks; each block is 1 day apart
It is measured thanks to the force-speed profile using two sprints of 7s with braking forces of 0 , 4 and 0.7 N.kg-1 respectively.
At the end of the 1st, 2nd and 3rd block : Each block = 2 weeks; each block is 1 day apart
Maximum theoretical speed (m/s)
Time Frame: At the end of the 1st, 2nd and 3rd block : Each block = 2 weeks; each block is 1 day apart
It is measured thanks to the force-speed profile using two sprints of 7s with braking forces of 0 , 4 and 0.7 N.kg-1 respectively.
At the end of the 1st, 2nd and 3rd block : Each block = 2 weeks; each block is 1 day apart
Maximum isometric force (N.m)
Time Frame: At the end of the 1st, 2nd and 3rd block : Each block = 2 weeks; each block is 1 day apart
It is measured by means of a voluntary maximum contraction test in which the maximum force generated voluntarily is compared to that voluntarily generated force will be compared to that evoked using electrical stimulation of the femoral nerve.
At the end of the 1st, 2nd and 3rd block : Each block = 2 weeks; each block is 1 day apart
heart rate variability (HRV)
Time Frame: At the end of the 1st, 2nd and 3rd block : Each block = 2 weeks; each block is 1 day apart
At the end of the 1st, 2nd and 3rd block : Each block = 2 weeks; each block is 1 day apart
Lactate (mmol/l)
Time Frame: At the end of the 1st, 2nd and 3rd block : Each block = 2 weeks; each block is 1 day apart
Blood sample
At the end of the 1st, 2nd and 3rd block : Each block = 2 weeks; each block is 1 day apart
Cytokines (pg/ml)
Time Frame: At the end of the 1st, 2nd and 3rd block : Each block = 2 weeks; each block is 1 day apart
Blood sample
At the end of the 1st, 2nd and 3rd block : Each block = 2 weeks; each block is 1 day apart
Creatine Kinase (UI/l)
Time Frame: At the end of the 1st, 2nd and 3rd block : Each block = 2 weeks; each block is 1 day apart
Blood sample
At the end of the 1st, 2nd and 3rd block : Each block = 2 weeks; each block is 1 day apart
muscle microRNA
Time Frame: At the end of the 1st, 2nd and 3rd block : Each block = 2 weeks; each block is 1 day apart
Blood sample
At the end of the 1st, 2nd and 3rd block : Each block = 2 weeks; each block is 1 day apart

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Hospitalier Universitaire de Saint Etienne

Investigators

  • Principal Investigator: Leonard FEASSON, MD-PhD, Centre Hospitalier Universitaire de Saint Etienne

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 27, 2021

Primary Completion (Actual)

March 8, 2023

Study Completion (Actual)

March 29, 2023

Study Registration Dates

First Submitted

August 10, 2021

First Submitted That Met QC Criteria

August 18, 2021

First Posted (Actual)

August 19, 2021

Study Record Updates

Last Update Posted (Actual)

July 19, 2023

Last Update Submitted That Met QC Criteria

July 18, 2023

Last Verified

June 1, 2022

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 20CH238
  • ANSM (Other Identifier: 2024-A02435-42)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe